Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for ocriplasmin (Jetrea®) for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ?400 microns. VMT is an age-related progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness. It is estimated to affect between 250,000 to 300,000 patients in Europe.
Ocriplasmin is a recombinant form of human plasmin, administered as a single intravitreal injection. It targets the protein fibres which cause the abnormal pulling between vitreous and macula that causes VMT. By dissolving these proteins, ocriplasmin releases the traction, and helps to complete the detachment of the vitreous from the macula. It may therefore prevent further damage to the vision and a need for vitrectomy in a small percentage of patients. The most common side effects include ...
Uncategorized